• Non ci sono risultati.

Malattia triplo negativa

N/A
N/A
Protected

Academic year: 2022

Condividi "Malattia triplo negativa"

Copied!
31
0
0

Testo completo

(1)

Terapia neo-adiuvante

MALATTIA TRIPLO NEGATIVA

Gaia Griguolo

DiSCOG - Università di Padova

Oncologia Medica 2 - Istituto Oncologico Veneto IRCCS

(2)

Neoadjuvant treatment for TNBC: what is the aim?

Cortazar P, et al. Lancet Oncol 2014

pCR

and long-term outcome in TNBC

Symmans et al. J Clin Oncol 2017

Residual Cancer Burden and long-term outcome in TNBC

TNBC N=219

(3)

• Platinum salts

• PARPi

• Immune-checkpoints inhibitors

• Predictive markers

Neoadjuvant treatment for TNBC:

what was new in 2017?

(4)

• Platinum salts

• PARPi

• Immune-checkpoints inhibitors

• Predictive markers

Neoadjuvant treatment for TNBC:

what was new in 2017 2018?

(5)

• Platinum salts

• PARPi

• Immune-checkpoints inhibitors

• Predictive markers

Neoadjuvant treatment for TNBC:

what was new in 2017 2018 2019?

The Old and Debated

The New and Shiny

The Sacred Graal

(6)

0 10 20 30 40 50 60

TAC Gepar31

EC-D EC-D+Bev Gepar53

PM PM+Cb (+ Bev) Gepar64

Evidence for Platinums in TNBC: pCR rates

(breast/axilla)

P-AC P+Cb-AC (+/- Bev) CALGB406035

P+Cb+bev

Ca.Pa.Be6 nabP-EC

Gepar78 EC-P

(+/-gem) NeoTango2

nabP-Cb ADAPT7

1. Huober J, BCRT 2010; 2. Earl HM, Lancet Oncol 2014; 3. von Minckwitz, NEJM 2012; 4. von Minckwitz, Lancet Oncol 2014; 5. Sikov, J Clin Oncol 2015; 6. Guarneri V, Ann Surg Oncol 2015; 7. Gluz O, SABCS 2015; 8. Untch M, Lancet Oncol 2016; 9. Loibl S, Lancet Oncol 2018

P+Cb-AC P+Cb+Vel-AC P-AC Brightness9

(7)

Poggio et al, Ann Oncol2018

The Best Evidence in TNBC: Platinum increases pCR

All trials Only trials with the same chemo

in both arms +/- platinum

(8)

The Best Evidence in TNBC: Platinum increases pCR

CALGB 40603

Standard arm +/-bevacizumab: 41% pCR breast/axilla Platinum arm +/-bevacizumab: 54% pCR breast/axilla

OR 1.71 p=0.0029

BRIGHTNESS

Standard arm: 31% pCR breast/axilla Platinum arm: 58% pCR breast/axilla

P<0.001

∆ 13% ∆ 27%

(9)

Evidence for Platinums in TNBC: Impact on Survival is uncertain

CALGB 40603 GEPARSIXTO

HR 0.99 (0.70-1.40) p=0.942

Standard arm : 76.1% 3-yr EFS Platinum arm : 85.8% 3-yr EFS Median follow-up 47 months

HR 0.56 (0.34-0.93) p=0.022 One study

Subgroup analysis (TNBC pts) No cytoxan in standard arm

Sikov WM et al. ASCO 2019

Untch M et al. ESMO 2017; Ann Oncol 2018

One study

Not powered to assess impact on EFS Same standard chemo +/- carboplatin

(10)

Evidence for Platinums in TNBC: Impact on Survival is uncertain

Metanalysis are not going to solve this uncertainty, data from more trials will

Evidence for Platinums in TNBC: Impact on toxicity is certain

Poggio et al, Ann Oncol2018

But schedule matters:

- Carboplatin AUC 5-6 q3w - Carboplatin AUC 2 – 1,5 qw

(11)

Neoadjuvant platinum for TNBC: recommendations

Linee guida AIOM 2018; Early Breast Cancer: St Gallen International Consensus Guidelines for the Primary Therapy of Early Breast Cancer 2019

The Panel voted against the routine inclusion of platinum-based

chemotherapy in women already slated to receive alkylator-, taxane- , and anthracycline-based regimens.

(12)

What are we not taking into account?

What comes after neoadjuvant treatment

Cortazar P, et al. Lancet Oncol 2014

pCR

and long-term outcome in TNBC

Still debated, but definitely out there

(13)

Evidence for Platinums in TNBC:

benefit is not limited to BRCA mut

Non solo BRCA

BRCA mutated BC patients

BC patients without BRCA

mutation

Poggio F. et al. Ann Oncol 2018

(14)

• Platinum salts

• PARPi

• Immune-checkpoints inhibitors

• Predictive markers

Neoadjuvant treatment for TNBC:

what was new in 2017 2018 2019?

The Old and Debated

The New and Shiny

The Sacred Graal

(15)

PARPi for neoadjuvant treatment of TNBC: I-SPY2

(16)

Platinum arm: 58% pCR breast/axilla Platinum+veliparib arm: 53% pCR breast/axilla

P=0.357

BRIGHTNESS Trial

(17)

GeparOLA trial

Primary endpoint - pCR

N+ population: 24.5% in PO vs 45.7% in PCb

Olaparib-Paclitaxel pCR Rate (95% CI)

Carboplatin-Paclitaxel pCR Rate (95% CI) HR+ (n=29) 52.6% (32.0-72.6) 20.0% (3.7-50.7) HR- (n=77) 56.0% (43.4-68.0) 59.3% (41.7-75.2) Age <40 76.2% (56.3-90.1) 45.5% (20.0-72.9) Age ≥40 45.8% (33.4-58.6) 50.0% (32.7-67.3)

g/t BRCA 1/2 mutation: 60.4%

PRIMARY ENDPOINT

- Assess pCR rate of neoadjuvant paclitaxel-olaparib (PO) → EC in HRD pts

- A rate in the PO arm of 55% or lower should be excluded with α=0.1 to support a subsequent phase III trial

- No formal comparison between arms

(18)

Neoadjuvant Talazoparib for BRCA mut TNBC

Litton et al, JCO 2019

(19)

Litton et al, JCO 2019

Neoadjuvant Talazoparib for BRCA mut TNBC

(20)

• Platinum salts

• PARPi

• Immune-checkpoints inhibitors

• Predictive markers

Neoadjuvant treatment for TNBC:

what was new in 2017 2018 2019?

The Old and Debated

The New and Shiny

The Sacred Graal

(21)

Immuno for neoadjuvant treatment of TNBC: I-SPY2

(22)

Loibl S, ASCO 2018, Ann Oncol 2019

GeparNUEVO trial

(23)

KEYNOTE-522: phase III trial

Carbo AUC 5 D1 or AUC 1,5 D1,8,15

Carbo AUC 5 D1 or AUC 1,5 D1,8,15

Dual-primary endpoints:

• pCR

• EFS

1174 patients

(24)

HIGH RISK PRIMARY TNBC PTS WHO COMPLETED TREATMENT

WITH CURATIVE INTENT INCLUDING SURGERY, CHEMOTHERAPY AND RADIOTHERAPY (if indicated)

Stratum A: Adjuvant Stratum B: Post-neoadjuvant

R

Avelumab for 1 year Observation

Co-primary endpoints: 1. DFS in all-comers; 2. DFS in PD-L1+ patients Secondary endpoints: OS, Safety, Biomarkers

n=335 (for the 1st co-primary endpoint)

Randomization 1:1 balanced for adjuvant and post-neoadjuvant patients.

(25)

• Platinum salts

• PARPi

• Immune-checkpoints inhibitors

• Predictive markers

Neoadjuvant treatment for TNBC:

what was new in 2017 2018 2019?

The Old and Debated

The New and Shiny

The Sacred Graal

(26)

TILs in TNBC at St.Gallen 2019

• Clinical utility still to be demonstrated However:

• Reproducible and standardized

• LoE1B clinical validity

• Provide additional prognostic info for discussion with patient

• Cheap, quick

Loi S, J Clin Oncol 2019

(27)

High TILs are associated with increased pCR rates and with EFS beyond pCR

Denkert C, Lancet Oncol 2018

(28)

High TILs in residual disease are associated with better EFS and OS

Luen SJ et al, Ann Oncol 2019

(29)

Heterogeneity in TNBC to identify targets

Lehmann et al, JCI 2011

Basal-like 1: cell cycle, DNA repair and proliferation genes

Basal-like 2: growth factors (EGFR, MET, Wnt, IGF1R)

Immunomodulatory: Immune signalling

Mesenchymal-like and

Mesenchymal stem-like: EMT, motility and growth-factor pathways

Luminal AR: Androgen receptor signaling

(30)

TNBC subtypes predict for response to CT

Masuda et al, CCR 2013; Echavarria Diaz-Guardamino et al, ASCO2018

(31)

GRAZIE

DELLA VOSTRA

ATTENZIONE

Riferimenti

Documenti correlati

This research shows how the reuse of abandoned buildings and related open spaces constitutes a significant opportunity for achieving more liveable and healthier cities through

For this reason and in order to decrease the treatment duration and increase quality of life of patients, partial breast irradiation (PBI) using interstitial brachytherapy

biopsy (including skin) through reddened area and include adjacent normal skin (some recommend FNA because clinical grounds confirm stage of dis- ease and you just want a dx of

The goal of minimally invasive therapy for breast cancer is to eradicate cancer cells with minimal damage to the underlying normal breast parenchyma or skin.. Tumor ablation is seen

Adjuvant chemo- therapy for early breast cancer in patients under 50 years old reduces the relative risk of recurrence by 35% and death by 27%, and for patients with

Indeed, although nearly all the trials comparing the com- bination of trastuzumab þ lapatinib versus trastuzumab alone (in association with chemotherapy) for the neo-

The search for glasses possessing required optical and thermal properties is fundamental in view of obtaining optical fibers, including fibers doped with high rare-earth (RE)